176 related articles for article (PubMed ID: 35570157)
1. Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems.
Sokhi HK; Wilson A; Pindoria N; McNamara C; Padhani AR; Meer Z; Pope A
Clin Radiol; 2022 Jul; 77(7):541-547. PubMed ID: 35570157
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer.
Zawaideh JP; Sala E; Pantelidou M; Shaida N; Koo B; Caglic I; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
Br J Radiol; 2020 Aug; 93(1112):20200298. PubMed ID: 32479105
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice.
Sokhi HK; Padhani AR; Patel S; Pope A
Clin Radiol; 2020 Dec; 75(12):950-956. PubMed ID: 32919755
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
5. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
Mehralivand S; Bednarova S; Shih JH; Mertan FV; Gaur S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
J Urol; 2017 Sep; 198(3):583-590. PubMed ID: 28373133
[TBL] [Abstract][Full Text] [Related]
6. Is Likert better than PI-RADS at predicting prostate cancer on MRI and can a mathematical algorithm achieve similar results?
Stevens W; Parchment-Smith C; Adiotomre E; Hulson O; Khan A; Melling P; Pierre S; Smith J
Acta Radiol; 2023 Sep; 64(9):2659-2666. PubMed ID: 37438925
[TBL] [Abstract][Full Text] [Related]
7. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
[TBL] [Abstract][Full Text] [Related]
8. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
[TBL] [Abstract][Full Text] [Related]
10. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
11. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
Yilmaz EC; Lin Y; Belue MJ; Harmon SA; Phelps TE; Merriman KM; Hazen LA; Garcia C; Johnson L; Lay NS; Toubaji A; Merino MJ; Patel KR; Parnes HL; Law YM; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
AJR Am J Roentgenol; 2024 Jan; 222(1):e2329964. PubMed ID: 37729551
[No Abstract] [Full Text] [Related]
12. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
[TBL] [Abstract][Full Text] [Related]
14. A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy.
Pal RP; Ahmad R; Trecartan S; Voss J; Ahmed S; Bazo A; Lloyd J; Walton TJ
J Urol; 2018 Aug; 200(2):302-308. PubMed ID: 29477717
[TBL] [Abstract][Full Text] [Related]
15. Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study.
Bittencourt LK; Guricova K; Zucker I; Durieux JC; Schoots IG
Eur Radiol; 2022 Apr; 32(4):2330-2339. PubMed ID: 35028750
[TBL] [Abstract][Full Text] [Related]
16. Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer.
Israël B; Immerzeel J; van der Leest M; Hannink G; Zámecnik P; Bomers J; Schoots IG; van Basten JP; Debruyne F; van Oort I; Sedelaar M; Barentsz J
BJU Int; 2022 Apr; 129(4):480-490. PubMed ID: 34358388
[TBL] [Abstract][Full Text] [Related]
17. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
18. Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer.
Khoo CC; Eldred-Evans D; Peters M; Bertoncelli Tanaka M; Noureldin M; Miah S; Shah T; Connor MJ; Reddy D; Clark M; Lakhani A; Rockall A; Hosking-Jervis F; Cullen E; Arya M; Hrouda D; Qazi H; Winkler M; Tam H; Ahmed HU
BJU Int; 2020 Jan; 125(1):49-55. PubMed ID: 31599113
[TBL] [Abstract][Full Text] [Related]
19. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
[TBL] [Abstract][Full Text] [Related]
20. Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?
Mayor N; Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor MJ; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Shah T; Ahmed HU
BJU Int; 2024 Jan; 133(1):112-117. PubMed ID: 37591614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]